| Symbol | BWAY |
|---|---|
| Name | BRAINSWAY LTD. |
| Sector | HEALTH CARE |
| Region | Asia |
| Industry | - |
| Address | 9777518 Israel 19 Hartum St. Bynet Building, 3rd Floor Har Hotzvim, |
| Telephone | (+972-2) 582-4030 |
| Fax | 02-5812517 |
| hadarl@brainsway.com | |
| Website | http://www.brainsway.com |
| Incorporation | IL |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;TASE;NASDAQ |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001505065 |
| Description | BrainsWay is dedicated to developing and providing advanced technology solutions for the treatment of a variety of brain disorders. The company was established in 2003, and became a public company traded on the Tel-Aviv Stock Exchange in January 2007. BrainsWays flagship technology is Deep-TMS, or Deep Transcranial Magnetic Stimulation, which launches a new era in brain disorder treatment. Additional info from NASDAQ: Additional info from OTC: |
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™
Read moreBrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation
Read moreBrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing SuicidalIdeation
Read moreBrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
Read moreBrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026
Read moreNew Form SCHEDULE 13G/A - Brainsway Ltd. <b>Filed:</b> 2026-07-29 <b>AccNo:</b> 0001178913-26-003637 <b>Size:</b> 9 KB
Read more